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Abstract
Transforming growth factor (TGF)-β has been shown to play a central role in the development of tubulointerstitial
ﬁbrosis, which can be corrected via treatment with paclitaxel. The biology of microRNA (miR) can be modulated by
paclitaxel. We hypothesized that paclitaxel may attenuate renal ﬁbrosis in a rat model of remnant kidney disease
by inhibiting TGF-β induced-miRs. Rats in groups of 12 were subjected to 5/6 nephrectomy and received low-dose
intraperitoneal injection of paclitaxel. Renal functions were assessed at 8 weeks. The TGF-β signalling cascade
and ECM proteins were evaluated by real-time polymerase chain reaction (TRT–PCR) and immunoﬂuorescence
microscopy. Animals with remnant kidneys developed hypertension, which was not relieved with paclitaxel
treatment. However, paclitaxel treatment resulted in dampening the proteinuric response, reduction in serum
BUN, creatinine levels and urine protein:creatinine ratio and normalization of creatinine clearance. These effects
were accompanied by the inhibition of Smad2/3 activation, attenuation of renal ﬁbrosis and normalization
of integrin-linked kinase (ILK), COL(I)A1, COL(IV)A2 and α-SMA expression. Also, paclitaxel down-regulated
the expression of miR-192, miR-217 and miR -377, while miR-15 was up-regulated in the remnant kidney.
In vitro, in tubular epithelial cells (NRK-52E), paclitaxel also inhibited TGF-β1-induced Smad2/3 activation and
normalized ILK, COL(I)A1, COL(IV)A2 and α-SMA expression. Furthermore, ChIP analyses indicated that Taxol
suppressed Smad3-mediated miR-192 transcriptional activity. Over-expression of miR-192 in NRK-52E mimicked
the changes seen in the remnant kidney, while inclusion of miR-192 inhibitor in the culture medium blocked TGF-
β1-induced COL(I)A1 and COL(IV)A2 expression, while ILK and α-SMA were unaffected. These data suggest that
low-dose paclitaxel ameliorates renal ﬁbrosis via modulating miR-192 pathobiology and TGF-β/Smad signalling.
Copyright  2011 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
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Introduction
Renal ﬁbrosis, affecting either the glomerular or the
tubulointerstitial compartment, is a common sequel of
diverse chronic renal diseases. Tubulointerstitial ﬁbro-
sis is a progressive process that ultimately leads to
end-stage renal disease (ESRD), requiring dialysis or
kidney transplantation [1]. Among many factors, trans-
forming growth factor-β (TGF-β) is a major well-
characterized pro-ﬁbrogenic cytokine whose expression
is up-regulated in animal models of ﬁbrosis, includ-
ing in the remnant kidney model and also in human
counterparts [2]. It is believed that TGF-β modu-
lates the transition of renal tubular epithelial cells
to myoﬁbroblasts and the latter apparently synthesize
excessive amounts of extracellular matrix (ECM), thus
leading to renal ﬁbrosis [3–5]. This is supported by
the fact that blockade of TGF-β with the neutralizing
antibody, antisense-oligo, decorin or siRNA attenuates
renal scarring [6–9].
MicroRNAs (miRs) are short non-coding RNAs of
22 nt that have recently been shown to play an impor-
tant role in mammalian gene expression [10]. The miRs
induce post-transcriptional gene repression by blocking
protein translation (by binding to the 3  UTR of their
target genes) or by inducing mRNA degradation, and
thus play a central role in various physiological and
pathological processes. Recent evidence suggests that
miRs may regulate the expression of key genes relevant
to neoplastic processes and potentially other diseases
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as well [11–13]. In kidney, miRs have been reported
to play a role in podocyte development [14–16],
the pathogenesis of diabetic nephropathy [17–19] and
polycystic kidney disease [20]. miR-192, miR-217 and
miR-377 have been described to be up-regulated in dia-
betic mouse and mesangial cells treated with TGF-β or
exposure to high-glucose ambience [17–19]. Although
it seems that the biology of miRs and TGF-β are inter-
linked, the effects of renal miRs may be cell type-
speciﬁc, in contrast to TGF-β, which exerts its effect
on a wide variety of cells. TGF-β induces ECM-related
gene expression through a series of events follow-
ing activation of its receptor. Activated TGF-β recep-
tors stimulate the phosphorylation of receptor-regulated
Smad2 and Smad3 proteins (R-Smads), which in turn
form complexes with Smad4. This complex translo-
cates from the cytoplasm into the nucleus, where the
Smads regulate the transcription of target genes and
miRs expression. Inhibitory Smad7 acts in an oppos-
ing manner to the R-Smads, and down-regulates TGF-β
signalling [21,22]. Some previous studies have shown
that endogenous Smad-2, Smad-3 and Smad-4 bind
to microtubules in several cell lines, and the binding
provides a negative regulatory mechanism to modu-
late TGF-β activity [23]. Disruption of the microtubule
network by chemical agents, such as nocodazole and
colchicine, leads to ligand-independent Smad nuclear
accumulation and transcription of TGF-β-responsive
genes [24].
Paclitaxel is an anticancer agent which, by stabiliz-
ing polymerized microtubules and maintaining micro-
tubular assembly, arrests the cell cycle in the G0–G1
and G2–M phases and induces cell death [25,26].
Prolonged chemotherapeutic treatment with paclitaxel
has been associated with scleroderma-like changes or
pulmonary ﬁbrosis in some patients. It is notewor-
thy that inhibition of tumour cell proliferation can be
achieved only by the administration of high dosages of
paclitaxel. The inhibition of TGF-β–Smad signalling,
however, can be accomplished with a very low dose
of paclitaxel, which would minimally affect cell pro-
liferation and other cellular activities. Interestingly,
low-dose paclitaxel has been shown to inhibit collagen-
induced arthritis, hepatic ﬁbrosis and ﬁbrosis associ-
ated with systemic sclerosis in SCID mice [26–28].
Along similar lines, we previously reported that the
low-dose administration of paclitaxel in a rat unilat-
eral ureteral obstruction (UUO) model signiﬁcantly
reduces tubulointerstitial ﬁbrosis [29]. However, the
molecular mechanism(s) by which paclitaxel inhibits
renal ﬁbrosis and ECM genes’ transcription/translation
remains to be clearly deﬁned. In this regard, some of
the literature reports suggest that miRs play a signiﬁ-
cant role in cytokine responses induced by paclitaxel.
Murine macrophages incubated with paclitaxel had
signiﬁcantly increased expression of miR-155, miR-
147, miR-146a and miR-132 [30]. In view of the
above literature information, studies were initiated to
assess whether stabilization of microtubules with low-
dose paclitaxel (Taxol) is able to block TGF-β–Smad
signalling and inhibit miRs expression, and thereby
attenuate progressive renal injury in the 5/6 nephrec-
tomized rat model.
Materials and methods
Animals
Animal experiments were performed in accordance
with the regulations set by the Institutional Commit-
tee for the Care and Use of Laboratory Animals.
Adult male Wistar rats (250–300 g body weight) were
purchased from Shanghai Experimental Animal Cen-
tre of the Chinese Academy of Sciences, Shanghai,
China. The animals were housed at 22
◦C on a 12 hour
light–dark cycle and were allowed free access to food
and water.
Animal model
The animals were anaesthetized with an intraperitoneal
(i.p.) injection of freshly prepared Avertin. For genera-
tion of the remnant kidney model, 5/6 nephrectomy was
performed, as described previously [31]. Brieﬂy, ani-
mals underwent subtotal nephrectomy involving right
subcapsular nephrectomy and infarction of approxi-
mately two-thirds of the left kidney by ligation of the
posterior and one or two anterior extrarenal branches
of the renal artery. Four groups of rats, comprising
12 animals each (total = 48), were used: (I) Sham
group—on the day of operation these rats received i.p.
injection of phosphate buffer saline (PBS) and twice
weekly thereafter; (II) Sham + Taxol group—the rats
received an i.p. injection of paclitaxel (Taxol, Sigma,
St. Louis, MO, USA) at a dose of 0.3 mg/kg twice
weekly; (III) Rem group—the rats received and i.p.
injection of PBS and underwent subtotal nephrectomy;
(IV) Rem + Taxol group—the rats, in addition those
in group III, received an i.p. injection of Taxol. All
rats were euthanized at 8 weeks following surgery. Rat
serum was collected at day 0 and at 4 and 8 weeks for
creatinine determination. and 24 h urine samples were
collected from the metabolic cages at day 0 and weekly
thereafter for the determination of protein and creati-
nine excretion. At 8 weeks, the kidneys were harvested
for various biochemical and morphological studies. All
procedures were performed in accordance with institu-
tional guidelines for animal care.
Cell culture
Experimental protocol 1
Rat tubular epithelial cells (NRK-52E) from ATCC
were cultured in Dulbecco’s modiﬁed Eagle’s medium
(DMEM)–F12 medium supplemented with 10% fetal
bovine serum (FBS). At 70% conﬂuency the cells
were transferred into complete medium containing 1%
FBS and culture maintained in an atmosphere of 5%
CO2/95% air at 37
◦C. Four groups of experiments
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were performed: the Mock control group (treated only
with DMEM); the Taxol group (200 nM paclitaxel
was added to the cell culture), the TGF-β1 group
[5 ng/ml recombinant human TGF-β1( R & DS y s t e m s ,
Minneapolis, MN, USA) was added to the cell cul-
ture], and the TGF-β1 + Taxol group. After 48 h of
treatment, the cells were processed for various studies.
The experiments in vitro were basically designed to
mimic the in vivo conditions, since increased expres-
sion of TGF-β1 has been well described in the remnant
kidney model. All the experiments were carried out in
quadruplicate.
Experimental protocol 2
The cells were seeded in a 24-well plate at a density of
105 cells/well, using DMEM/F12 medium containing
5% fetal calf serum (FCS). By employing Lipofec-
tamine 2000, subconﬂuent cells were then transfected
with four different miRs: hsa-miR-192 mimic (50 nM);
negative control (miR-neg; Sigma); antisense-miR-192
(400 nM); or control antisense-miR (Genepharma,
Shanghai, China). After 24 h of transfection, the cul-
ture media were replaced with fresh medium and the
cells were allowed to achieve 80% conﬂuency, follow-
ing which the cells were maintained in a serum-free
medium overnight. They were then treated with either
0.1% BSA (control) or TGF-β1 (5 ng/ml) for another
24 h. Cell extracts were prepared from various exper-
iments for real-time PCR or western blot analyses and
immunoﬂuorescence studies.
Measurements of protein and creatinine
The rats were placed in individual metabolic cages
and 24 h urine collection was carried out. The urine
samples were centrifuged at 2000 × g for 5 min and
the supernatants were saved. Urine albumin was mea-
sured by enzyme-linked immunosorbent assay (ELISA;
Bethyl Laboratories, Montgomery, TX, USA). Urine
albumin excretion (UAE) was normalized with creati-
nine excretion and expressed per mg creatinine. Cre-
atinine levels in the urine and serum were measured
using the QuantiChrom Creatinine Assay Kit (BioAs-
say Systems, Hayward, CA, USA).
Blood pressure measurements
Systolic blood pressure (SBP) was measured in con-
scious rats by use of a non-invasive computerized
tail-cuff system (Model-1231, IIT Inc), as described
previously [32].
Morphological studies
Kidney tissues were ﬁxed with 4% buffered parafor-
maldehyde, embedded in parafﬁn, and 4 µmt h i c k
sections were prepared. The sections were then stained
with periodic acid–Schiff (PAS) and Masson’s trichro-
me [33]. The mean glomerular cross-sectional area
(glomerulosclerosis index, GSI) was determined in 50
glomerular sections from each rat [33]. All analyses
were performed in a blind manner. Segmental and
complete glomerular sclerosis were analysed using a
semiquantitative scoring system in the range 0–4 (0,
no glomerulosclerosis; 1, <25% of glomerular area
affected; 2, 25–50% affected; 3, 50–75% affected; 4,
75–100% affected); at least 50 glomeruli were eval-
uated under ×400 magniﬁcation and the results were
averaged. The tubulointerstitial injury score was esti-
mated. The GSI for each rat was calculated as a mean
value obtained from 50 glomeruli. The tubulointersti-
tial injury score was estimated based on the number of
tubule dilatations, the distortion of the tubular basement
membranes, and atrophy in the range 0–3 [0, none
(<5%); 1, mild (5–25%); 2, moderate (25–50%); 3,
severe (>50%)]. More than 10 consecutive ﬁelds were
examined at a magniﬁcation of ×400 [34]. The score
index in each rat was expressed as a mean value of all
scores obtained.
Real-time polymerase chain reaction
Total RNA was isolated using the High Pure RNA
Isolation Kit (Roche, Switzerland) according to the
manufacturer’s instructions. Contaminated DNA was
removed by treating the samples with RNAase-free
DNAase I (Promega, Madison, WI, USA). First-strand
cDNAs were generated using a superscript VILO
cDNA synthesis kit (Invitrogen). Real-time PCR was
performed using a Bio-Rad (Hercules, CA) IQ SYBR
Green Supermix with Opticon (MJ Research Inc.,
Waltham, MA, USA). The primer sets used for various
genes were as follows:
• Smad2:f o r w a r d5  -TCACAGCCATCATGAGCT
CAAGG-3 , reverse 5 -TGTGACGCATGGAA
GGTCTCTC-3 .
• Smad3:f o r w a r d5  -AGCACACAATAACTTGG
ACC-3 , reverse 5 -TAAGACACACTGGAACA
GCGGATG-3 .
• Integrin-linked kinase (ILK): forward 5 -CCGCT
GGCAGGG CAATGACATT-3 , reverse 5 -GGG
GGAGCCTGGCAAGCACCTA-3 .
• α2-Smooth muscle actin (α2-SMA): forward
5 -ACTGGGACGACATGGAAAAG-3 , reverse
5 -CATCTCCAGAGTCCAGCACA-3 .
• Collagen type I α1 (COL1A1): forward 5 -GAG
CGGAGAGTA CTGGATCG-3 , reverse 5 -TAC
TCGAACGGGAATCCATC-3 .
• Collagen type IV α2 (COL4A2): forward 5 -AC
ACTGTGGACTTACCAGG-3 , reverse 5 -CC
AGGAAATCCAATGTCACC-3 .
All samples were subjected to RT–PCR along with
the housekeeping gene GAPDH, having the following
primer sequences:
• GADPH:f o r w a r d5  -TGCTGAGTATGTCGTGG
AGTCTA-3 , reverse 5 -AGTGGGAGTTGCTG
TTGAAATC-3 
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as an internal standard control. The PCR conditions
were as follows: 94
◦C for 2 min, followed by 40 cycles
of (94
◦C for 15 s, 58
◦C for 30 s and 72
◦C for 30 s)
and a ﬁnal extension at 72
◦C for 10 min.
miRNA extraction and microarray analysis
miRNAs were extracted from isolated tubular cells
or renal cortices enriched with tubules or NRK52E
tubular cell lines from different experimental vari-
ables (Figure 5), using a miRNwasy Mini Kit (Qia-
gen, Valencia, CA, USA). miRNA microarray proce-
dures were performed at Beijing Capital Biological
Corporation. Brieﬂy, isolated miRNA was covalently
linked with either Cy3 (green channel) or Cy5 (red
channel). Pairs of labelled samples were hybridized
to dual-channel microarrays. A double-channel laser
ﬂuorescence scanner was used for microarray anal-
yses, and the data were analysed as described pre-
viously [35]. Successful array submission was made
to MIAMExpress (http://www.ebi.ac.uk/miamexpress),
array design name ‘Taxol-treatment-mechanism’.
Northern blot analysis of miRNA
Total RNA was extracted from kidney cortices using
Trizol (Invitrogen). Low-molecular weight RNA was
subsequently isolated by precipitation in PEG 8000/
NaCl, as previously described [36]. Low-molecular
weight RNA (50 µg) was run on a denaturing 10%
polyacrylamide gel, transferred to PVDF membrane
(Amersham/GE Healthcare, Piscataway, NJ, USA),
subjected to UV light irradiation for 4 min and
baked at 80
◦C for 1 h. The locked nucleic acid
(LNA)-modiﬁed miR-192 oligonucleotide probe (5 -
CTGACCTATGAATTGACAGCC-3 ) was purchased
from Exiquon (Woburn, MA, USA). The probe was
5 -end-labelled with (γ-32P) ATP (Perkin-Elmer Life
Sciences). Signals were quantiﬁed using National Insti-
tutes of Health Image J version 1.42q software.
Detection of miRNA expression
Total RNA was extracted from kidney. The RNA
samples were reverse-transcribed to cDNA using the
mirVanat qRT–PCR miRNA detection kit (Ambion).
Real-time PCR was carried out using SYBR Pre-
mix EXTaqTM (Takara), following the manufacturer’s
instructions. The miR-192, miR-217, miR-337 and
miR-15a primer sets were purchased from RiBi Biolog-
ical Corporation (Guangzhou, China). The input was
normalized with U6 smRNA. Data were shown as fold
change (2−  Ct) and analysed using Opticon Monitor
Analysis software v2.02 (MJ Research, Waltham, MA,
USA).
Immunoﬂuorescence and immunohistochemistry
Cells were grown on coverslips, washed twice with
PBS, ﬁxed in 4% paraformaldehyde for 20 min, per-
meabilized using 0.1% Triton X-100 and incubated
in a blocking buffer (1% BSA, 0.25% Triton X-100
in PBS, pH 7.4). Primary and secondary antibodies
were diluted in a blocking buffer and incubated with
cells overnight at 4
◦C. After DAPI staining the cover
slips, including the cells, were mounted onto glass
slides after placing a drop of Prolog Gold Antifade
reagent. The cells were then viewed using a ﬂuo-
rescence microscope. For tissue immunoﬂuorescence
studies, cryostat sections (4 µm thick) were ﬁxed in
cold acetone and then incubated with mouse mon-
oclonal anti-COL(I)A1 (Abcam) or rabbit polyclonal
anti-COL(IV)A2 (Abcam) antibody for 1 h, followed
by another incubation with FITC-labelled anti-mouse
or rabbit IgG (Biosource International, Camarillo, CA,
USA). Immunohistochemical analyses were carried out
by using rabbit anti-phospho-Smad2/3 (Santa Cruz
Biotechnology) and mouse monoclonal anti-α-SMA
(Santa Cruz). The sections were deparafﬁnized and
quenched with 3% H2O2 for 10 min to block endoge-
nous peroxidase and then washed in PBS. They were
incubated with various primary antibodies, as listed
above, for 1 h and then with biotinylated secondary
antibody, followed by ABC reagent treatment as rec-
ommended by the vendor. Colour development was
achieved by incubating the sections with diaminoben-
zidine (DAB) as substrate. The slides were counter-
stained with Mayer’s haematoxylin. Preincubation of
the primary antibody with speciﬁc blocking peptides
or substitution of the primary antibody with an irrele-
vant IgG served as negative controls. The slides were
examined using an Olympus microscope equipped with
UV epi-illumination. The intensity of ﬂuorescence was
analysed by image analysis software (Path QC, Logene
Biological Medical Engineering Co. Ltd).
Western blotting
Western blot analyses were carried out as described
previously [33]. Brieﬂy, samples (20 µg protein)
were subjected to SDS–PAGE. After transfer of
proteins onto the nitrocellulose membrane (Amer-
sham), the blots were probed with the following anti-
bodies: mouse monoclonal anti-α-SMA (Santa Cruz;
1:1000 dilution), -COL(I)A1 (Abcam; 1:1000 dilu-
tion), rabbit polyclonal anti-phospho-Smad2/3 (Santa
Cruz Biotechnology; 1:1000 dilution), -COL(IV)A2
(Abcam; 1:1000 dilution) and -ILK (Santa Cruz;
1:1000 dilution). A peroxidase-conjugated goat anti-
mouse IgG (1:20 000 dilution) was used as a sec-
ondary antibody. Pig anti-rabbit IgG or rabbit anti-goat
in PBS containing 1% normal goat serum and 1% FCS
and β-actin were used as internal controls.
ChIP analysis
Chromatin immunoprecipitation (ChIP) analysis was
performed using a transcription factor ChIP kit accord-
ing to the manufacturer’s instructions. In brief, cells
were cross-linked with 1% formaldehyde for 10 min at
37
◦C, quenched with glycine and then sonicated, using
a Bioruptor (Diagenode, Li` ege, Belgium) to generate
300–600 bp DNA fragments. Immunoprecipitation
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Figure 1. Effect of paclitaxel (Taxol) on blood pressure and renal functions of rats with remnant (Rem) kidney. (A) Systolic blood pressure;
(B) 24 h urinary protein excretion; (C) serum creatinine; (D) protein:creatinine ratio; (E) creatinine clearance; (F) BUN. All the renal
functional parameters were almost normalized with Taxol treatment in the Rem group; however, the blood pressure was unaffected by
Taxol treatment. Data represent mean ± SEM for groups of 12 rats treated with Taxol.  p < 0.05 versus Sham or Sham + Taxol groups;
#p < 0.05 versus Rem group (n = 12).
was performed with the antibody directed against
Smad3 (Upstate) and IgG was used as a control.
Precipitated DNAs were subjected to PCR analysis
using speciﬁc primers as follows: for Smad binding
site 1 (SBS1), 5 -AGCCAAGTGTCTCTCCGTGT-3 
and 5 –GGTGGCAGGAGGTGTGTACT-3 ;f o rS m a d
binding site 2 (SBS2), 5 -CACTGTCCCAACATGCT
CAC-3  and 5 -GGTAGCAGGGAGAAGCAATG-3 .
The reaction mix consisted of 1.5 µl template, 5.0 µl
2× Bio-RadiQSYBR Green supermix, 0.3 µlf o r -
ward primer, 0.3 µl reverse primer and 2.9 µl double-
distilled H2O. qPCR was performed as described above
for quantitative real-time PCR.
Statistical analysis
Data were expressed as mean ± SD and one-way
analysis of variance (ANOVA) was carried out. p<
0.05 was considered statistically signiﬁcant.
Results
Biochemical data
Rats that had undergone subtotal nephrectomy devel-
oped hypertension at the end of the second week
and it was not relieved by the paclitaxel (Taxol)
treatment (Figure 1A). These rats (designated the
Rem group) developed progressive renal injury, as
reﬂected by an increase in 24 h urinary protein excre-
tion (Figure 1B), rise in serum creatinine (Figure 1C),
proteinuria:creatinine ratio (Figure 1D) and blood urea
nitrogen (BUN) (Figure 1F), and decline in crea-
tinine clearance (Figure 1E). In contrast, paclitaxel
treatment blunted the proteinuric response, rise in
serum creatinine, protein:creatinine ratio and BUN
(Figure 1B–D, F; p<0.05), and prevented the drop in
creatinine clearance after 5/6 nephrectomy (Figure 1E;
p<0.05).
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Figure 2. Effect of Taxol on renal morphology of rat remnant kidney. Kidney sections were stained with PAS (A) and Masson’s trichrome
(B). There were remarkable changes in both glomerular and tubulointerstitial compartments in the remnant kidney, which were notably
reduced by the Taxol treatment. (C) Morphometric analyses conﬁrmed the morphological changes seen in various groups. Magniﬁcation,
×400.  p < 0.05 versus Sham or Sham + Taxol groups; #p < 0.05 versus Rem group (n = 12).
Effects of paclitaxel on morphology in the remnant
kidney
At 8 weeks after surgery, notable glomerulosclerosis
and tubulointerstitial ﬁbrosis was observed, as assessed
by PAS and Masson’s trichrome staining (Figure 2A,
B). In the 5/6 nephrectomy kidneys the glomeru-
losclerosis index (GSI) was ∼11-fold higher compared
to Sham control kidneys and interstitial expansion
was also a prominent feature. Treatment with Taxol
signiﬁcantly reduced the progression of glomerular
injury and interstitial expansion. The glomerular cross-
sectional area was notably reduced in the Rem + Taxol
group compared to the Rem group (Figure 2C, 1.99 →
1.12). Also, tubulointerstitial ﬁbrosis was signiﬁcantly
reduced by Taxol treatment (Figure 2C, 1.86 → 0.44).
Inhibition of Smad2/3 activation and reduction of
ECM expression following Taxol treatment in the
remnant rat kidney
The effects of Taxol on mRNA and protein expres-
sion of ILK, COL(I)A1, COL(IV)A2 and α-SMA were
determined by real-time reverse transcription–poly-
merase chain reaction (TRT–PCR) and immunoﬂuo-
rescence microscopy. TRT–PCR analyses showed that
Taxol has no effect on ILK, COL(I)A1, COL(IV)A2
and α-SMA expression in Sham-operated rat kid-
neys, while it remarkably reduced their expression
in the remnant kidney (Figure 3A). Taxol had no
effect on Smad2 and Smad3 mRNA expression in
Sham-operated or remnant kidneys. Immunoﬂuores-
cence microscopy and immunohistochemistry revealed
a notable reduction in the expression of Collagen I,
Collagen IV, α-SMA and the phosphorylated forms of
Smad2/3 with Taxol treatment in the remnant kidney
(Figure 3B). The RT–PCR data are representative of
six experiments.
Taxol inhibits TGF-β1-induced expression of ILK,
COL(I)A1, COL(IV)A2, α-SMA, and Smad2/3
phosphorylation in renal tubular epithelial cells
The effect of Taxol on mRNA and protein expres-
sion of ILK, COL(I)A1, COL(IV)A2, α-SMA, Smad2
and Smad3 were determined by TRT–PCR and west-
ern blot analyses. TRT–PCR analyses indicated that
Taxol signiﬁcantly reduced the expression of ILK,
COL(I)A1, COL(IV)A2 and α-SMA in TGF-β1-treated
NRK52E cells; however, no effect was seen on
Smad2 and Smad3 (Figure 4A). Western blot anal-
yses conﬁrmed the results observed in the above
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Figure 3. Effect of Taxol on ILK, collagen, phosphorylated Smad2/3 (p-Smad) and α-SMA expression in the rat remnant kidney. (A) Real-
time PCR analyses revealed that Taxol inhibited the expression of ILK, COL(I)A1, COL(IV)A2 and α-SMA in the rat remnant kidney (p < 0.05,
n = 12). No differences in Smad2 and Smad3 mRNA expression were observed in various experimental groups. (B) Immunoﬂuorescence
microscopy showed that expression of COL(I)A1 and COL(IV)A2 was signiﬁcantly increased in the remnant kidney (p < 0.05, n = 12) and
notably reduced with Taxol treatment (p < 0.05, n = 12). (C) Immunohistochemistry showed that expression of p-Smad2/3 and α-SMA
was signiﬁcantly increased in the remnant kidney (p < 0.05, n = 12) and notably reduced with Taxol treatment (p < 0.05, n = 12). Data
of each bar represents mean ± SEM for 12 animals.  p < 0.05 versus Sham group (n = 12); #p < 0.05 versus Rem group. Magniﬁcation,
×400.
gene expression following Taxol treatment in TGF-β1-
stimulated NRK52E cells (Figure 4B). Also, Taxol
had no effect on the protein expression of Smad2/3,
but the phosphorylated form was signiﬁcantly reduced
(Figure 4C).
Regulation miRNAs expression by Taxol
Comparative microarray analysis of intact kidney tissue
(cortices from remnant kidney), isolated renal tubular
epithelial cells and TGF-β1-treated (5 ng/ml) NRK52E
cells revealed that the changes in expression were
mainly conﬁned to three miRNAs (Figure 5A). Taxol
down-regulated miR-192, miR-217 and miR-377 in
remnant kidney, while it up-regulated miR-15a by
microarray (Figure 5B, C) and real-time PCR analyses
(Figure 5D). Since the most remarkable changes were
seen in miR-192, the studies were extended and its
expression was also assessed by northern blot analyses
in the remnant kidney. In the remnant kidney, the
miR-192 expression increases notably by 4 weeks,
and by 8 weeks a steep increase was observed. The
expression was dramatically reduced with the Taxol
treatment (Fig 5E, F). Furthermore, we used a ChIP
assay to determine the interaction of Smad3 with
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Figure 4. Effect of Taxol on ILK, Collagen, phosphorylated Smad2/3 (p-Smad), Smad2, Smad3 and α-SMA expression in NRK52E cells.
(A) Real-time PCR analyses showed that ILK, Collagen and α-SMA were signiﬁcantly higher in the TGF-β1 group compared to the Mock
group (p < 0.05, n = 6). Treatment with Taxol caused a signiﬁcant decrease in their expression in TGF-β1-treated NRK52E cells (p < 0.05,
n = 6). Smad2 and Smad3 mRNA expression were unaltered in the Taxol and TGF-β1 + Taxol groups. (B, C) Western blot analyses showed
that ILK, Collagen, p-Smad2/3 and α-SMA, but not total Smad2 or Smad3, expressions were signiﬁcantly higher in the TGF-β1g r o u p
compared to the Mock group (p < 0.05, n = 6), while treatment with Taxol reduced their expression (p < 0.05, n = 6).  p < 0.05 versus
Mock or Taxol groups (n = 6); #p < 0.05 versus TGF-β1g r o u p .
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Figure 5. Expression of miRNA in the rat remnant kidney, isolated tubular cells and TGF-β1-treated NRK52E cells. (A) Comparative
microarray analysis indicated that three miRNAs were up-regulated in all the samples. (B) Log2 values of each Rem + Taxol/Rem pair
of miRNA microarray signals were displayed in a heat map generated by a TIGR multi-experiment; red indicates up-regulation, green
down-regulation and black no change. The bar code (−4t o+4) at the top represents the colour scale of the log2 values. (C) Bar graph
indicating fold changes in the expression of miRNAs (miR-15a, miR-377, miR-217 and miR-192)i nR e m+ Taxol compared to that of
the Rem group. Taxol treatment reduced the expression of three miRNAs, especially that of miR192, as assessed by microarray analyses.
(D) Real-time PCR conﬁrmed the increased miR-192, miR-217 and miR-337 expression in the rat remnant kidney; these expressions
were signiﬁcantly higher in Rem rats than in Sham animals (p < 0.05, n = 12), and the expression was notably reduced following Taxol
treatment (p < 0.05, n = 12). No change was observed between the Sham and Sham + Taxol groups. (E) Northern blot analyses showed
the time-course effect of Taxol on miR-192 expression levels in the kidney of the rat remnant model. miR-192 expression increased
signiﬁcantly at 4 and 8 weeks following surgery and was substantially reduced with Taxol treatment. (F) Densitometry analyses of northern
blots from six independent experiments; each bar represents mean ± SEM for 12 animals. ∗p < 0.05 versus Rem group;  p < 0.05 versus
Sham group; #p < 0.05 versus Rem group (n = 12). (G) ChIP assays for Smad3 were performed with chromatin material isolated from
NRK52E cells treated with TGF-β1. Precipitated DNA was ampliﬁed with oligonucleotides spanning regions of the potential Smad binding
sites 1 and 2 (SBS1 and SBS2); total inputs are indicated. The antibody against Smad3 immunoprecipitated the DNA fragments from
NRK52E cells containing the potential SBS1 and SBS2, and their bindings were suppressed by Taxol.
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Figure 6. Effect of miR192 transfection on ILK, COL(I)A1, COL(IV)A2 and α-SMA expression in NRK52E cells. (A) Real-time PCR analyses
revealed that expression of miR192, ILK, COL(I) A1, COL(IV)A2 and α-SMA were markedly increased in TGF-β1-treated NRK52E cells
(p < 0.05, n = 6). Also, the expressions of COL(I)A1, COL(IV)A2 and miR192, but not of ILK and α-SMA, were increased in miR-192-
transfected NRK52E cells compared to Mock (p < 0.05, n = 6). The effects accentuated by TGF-β1 were abolished with the AS-miR-192
treatment (p < 0.05, n = 6). (B, C) Western blot analyses displayed similar results; data were derived from six independent experiments.
 p < 0.05 versus Mock group; #p < 0.05 versus TGF-β1g r o u p ; p < 0.05 versus miR192 group (n = 6).
the miR-192 promoter region in NRK52E cells. As
shown in Figure 5G, the antibody directed against
Smad3 immunoprecipitated the DNA fragments from
NRK52E cells containing the potential binding sites of
SBS1and SBS2, supporting the hypothesis that Smad3
can physically interact with the miR-192 promoter
region, and their activities were remarkably suppressed
by Taxol.
Modulation of COL(I)A1 and COL(IV)A2 expression
by miR-192 and TGF-β1 in NRK52E renal tubular
epithelial cells
Treatment with TGF-β1 induced an increase in the
expression of ILK, COL(I)A1, COL(IV)A2 and α-
SMA mRNA from the baseline (Mock) by TRT–PCR
(Figure 6A). The miR-192 transfection led to a two-
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Figure 7. Effect of miR192 transfection on COL(I)A1 and COL(IV)A2 expression in NRK52E cells, as assessed by immunoﬂuorescence
microscopy. The miR-192-transfected NRK52E cells had a signiﬁcantly increased expression of both collagen I and collagen IV compared
with the Mock group (p < 0.05, n = 6). Taxol treatment notably reduced the expression of both the ECM proteins, ie COL(I)A1 and
COL(IV)A2. #p < 0.05 versus Mock group (n = 6); p < 0.05 versus miR192 group (p < 0.05, n = 6).
to three-fold higher expression of COL(I)A1 and
COL(IV)A2 compared to the treatment with TGF-β1,
while that of ILK and α-SMA were indistinguishable
(Figure 6A). The transfection of AS-mIR-192 caused
a remarkable reduction in the expression of COL(I)A1
a n dC O L ( I V ) A 2i nT G F - β1-treated cells, while that of
ILK and α-SMA were unaltered. Western blot analyses
conﬁrmed the ﬁndings of the above gene expression
studies (Figure 6B, C). In view of this, immunoﬂuo-
rescence studies were also carried out to assess the
effect of Taxol. An increase in the cellular expression
of COL(I)A1 and COL(IV)A2 was observed with the
transfection of miR-192, and it was remarkably reduced
with Taxol treatment (Figure 7A, B).
Discussion
The data from this investigation suggest that low-
dose Taxol ameliorates renal ﬁbrosis with improvement
in renal functions in the rat remnant kidney model
by reducing collagen synthesis in the tubulointerstitial
compartment. The central mechanism seems to be that
Taxol interferes in the TGF-β1-induced downstream
signalling events, which include blockade of Smad2/3
activation and inhibition of miRNA-192, with a net
result of decreased expression of collagen both in vitro
and in vivo systems.
The remnant kidney model has been widely used
to study various pathogenetic mechanisms that lead
to tubulointerstitial ﬁbrosis and chronic kidney disease
(CKD). In CKD, TGF-β1 has long been considered
to be an important modulator of renal tubular biol-
ogy, with increased collagen production that ultimately
leads to ﬁbrosis and scarring of the kidney [37,38]. The
ﬁbrogenic effects of TGF-β1 are thought to be medi-
ated via the Smad2/3 pathway, where Smad3 plays
a critical role as a downstream signalling molecule
[21]. Loss of Smad3 activity has been shown to
yield protection from radiation-induced ﬁbrosis [39],
bleomycin-induced pulmonary ﬁbrosis [40] and tubu-
lointerstitial ﬁbrosis in the UUO model [41]. In the
orchestration of these events related to ﬁbrosis, cel-
lular microtubules (MTs) serve as negative regula-
tors of TGF-β/Smad signalling. They form a com-
plex with endogenous Smad2, Smad3 and Smad4, and
thus sequester receptor-Smads (R-Smads) away from
TGF-β receptor modulation [21]. Conceivably, the dis-
ruption or dynamic instability of the cellular MT net-
work leaves TGF-β uncomplexed and thus free to
exert its ﬁbrogenic effects. In this regard, stabiliza-
tion of MTs with low-dose Taxol has been shown
to dampen the exaggerated TGF-β signalling and
thus block TGF-β-induced inhibition of myogenesis in
C2C12 myoblasts [42,43]. Similarly, Taxol has been
reported to signiﬁcantly suppress TGF-β/Smad activ-
ity and ﬁbrosis in SCID mice and the rat UUO model
[28,29]. Along these lines, the present study provides
evidence that low-dose Taxol suppresses TGF-β/Smad
activity in the rat remnant kidney and TGF-β-induced
ECM expression in tubular epithelial cells.
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The ﬁnding that low-dose Taxol reduces the up-
regulation of COL(I)A1, COL(IV)A2 and α-SMA in
the rat remnant kidney without lowering the systemic
blood pressure suggests that the reno-protective effect
of paclitaxel is independent of angiotension II activ-
ity, etc., and is solely directed at ECM synthesis. It
is conceivable that stabilization of the MT network
maintains appropriate inside–out or outside–in sig-
nals and proper cellular homeostasis, so that excessive
synthesis of ECM does not occur. In inside–out or out-
side–in signalling the ILKs play a crucial role, since
these intracellular serine/threonine protein kinases are
known to regulate cell adhesion, survival and epithe-
lial–mesenchymal transition (EMT) [44]. Increasing
evidence suggests that inhibition of ILKs attenuates
renal interstitial ﬁbrosis, where ILK induction by
TGF-β1 is clearly dependent upon Smad signalling
in tubular epithelial cells [45]. The subject matter
of EMT is somewhat controversial, however; the up-
regulation of α-SMA and down-regulation by Taxol,
with concomitant decrease in the synthesis of colla-
gen, suggest that transformation of tubular cells to
myoﬁbroblasts, reminiscent of EMT, may occur at
least in vitro where TGF-β1 effects are nulliﬁed by
Taxol.
To further investigate the mechanisms by which
Taxol reduces ﬁbrosis in the rat remnant kidney
model, microarray analyses were carried out using
renal cortices, isolated renal tubular epithelial cell
and TGF-β1-treated NRK52E cells. The expressions
of three miRNAs, miR-217, miR-192 and miR-377,
were found to be consistently high, and they were
decreased with low-dose paclitaxel treatment in all
three different biological samples, ie cortices, iso-
lated tubular cells and NRK52E cells. The miR-217
is known to be involved in increased collagen pro-
duction and the progression of diabetic nephropathy
through the down-regulation of PTEN and the subse-
quent activation of Akt kinase, and similar Akt up-
regulation can be achieved by TGF-β-induced miR-
192 [18]. miR-377 is thought to regulate the expres-
sion of ﬁbronectin, another ECM protein that is up-
regulated in diabetic nephropathy. Expression of miR-
377 has been found to be up-regulated in various
mouse models of diabetic nephropathy and in cul-
tured human and mouse mesangial cells subjected
to a high-glucose ambience or treated with TGF-β1
[19]. The role of miR-192 in kidney diseases is
still controversial. Kato et al [17] described its up-
regulation in the glomeruli of type 1 and type 2 dia-
betic mice and in cultured mesangial cells treated with
TGF-β1. Kato et al and Chung et al have reported
that miR-192 was up-regulated in cultured mesan-
gial and tubular cells treated with TGF-β1 [18,46].
They also reported that TGF-β1-induced miR-192 up-
regulation in mesangial cells increased the expres-
sion of COL(I)A2 by down-regulating Zeb2, an E-box
repressor [17].
The ﬁndings of Wang et al and Krupa et al [47,48]
in rat proximal tubular and mesangial cells are contrary
to the results reported by Kato et al and Chung et al
[18,46]. Such differences may be related to the dif-
ferent culture conditions used. Kato et al used serum-
deprived cells to establish a baseline for measuring
the effect of TGF-β. They observed a 70% drop in
miR-192 expression with serum deprivation, which was
essentially reversed by TGF-β. In the Wang et al exper-
iments, under reduced serum conditions the TGF-β1
treatment resulted in a decrease rather than increase
in miR-192 levels. Kato et al and Chung et al [18,46]
also reported an increase in miR-192 in the diabetic
kidney, UUO and the rat 5/6 nephrectomy model, in
contrast to the Wang et al studies in diabetic kid-
neys, where miR-192 was decreased. The observed
differences are likely to be related to the different
model system used, and time points at which expres-
sion was assessed. Nevertheless, our data are con-
sistent with the Kato et al and Chung et al studies.
Furthermore, miR-192 is considered critical in down-
stream of TGF-β/Smad3 signalling in tubular epithelial
cells [46]. By using ChIP assays, we demonstrated
that an antibody directed against Smad3 could suc-
cessfully immunoprecipitate DNA fragments contain-
ing the potential Smad3-binding sites, thus support-
ing the Chung et al [46] ﬁndings that Smad3 could
physically interact with the promoter region of miR-
192, and that Taxol is capable of suppressing Smad3-
mediated miR-192 transcriptional activity. To test our
hypothesis that Taxol inhibits renal ﬁbrosis through
reduction of miR-192 levels, which down-regulate
ECM protein expression, miRNA in vitro experiments
were carried out. As expected, the tubular epithelial
cells over-expressing miR-192 mimic or treated by
TGF-β1 had signiﬁcantly increased expression of not
only miR-192 but also COL(I)A1 and COL(IV)A2.
On the other hand, transfection of antisense miR-192
reduced the gene and protein expression induced by
TGF-β1. These data indicate that miR-192 and ILK
may have independent actions that converge at the
downstream events related to TGF-β/Smad3 signalling
in the development of renal ﬁbrosis. The in vitro obser-
vations that miR-192 increases collagen expression,
which is down-regulated by Taxol and also in the
renal cortices of rat remnant kidney in vivo, under-
scores the signiﬁcance of miR-192 among the three
miRs in the pathobiology of interstitial ﬁbrosis in this
model.
In conclusion, low-dose Taxol signiﬁcantly improves
kidney functions and attenuates renal injury following
subtotal renal ablation in rats by modulating mir-192
biology, which seems to be intimately interlinked with
TGF-β/Smad signalling.
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